-
MDxHealth Q1 2023 resultaten
Ziet er op het eerste gezicht netjes uit …
“We are pleased to report strong operating results for the first quarter of 2023. Our focus on operating discipline and commercial execution, as well as continued implementation of our growth strategy, is building the foundation for sustained growth for mdxhealth as the leading provider of personalized diagnostic solutions focused exclusively into urology.
“I am also pleased to note that after successfully completing a rigorous technical assessment, we announced in April that Select mdx will now be reimbursed throughout the U.S. for Medicare patients who meet coverage conditions under the foundational Local Coverage Determination (LCD) for Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer. With this coverage decision, each of the tests in our prostate cancer menu is now covered by Medicare and included in the NCCN guidelines.”
Persbericht: https://mdxhealth.com/press_release/mdxhealth-reports-q1-2023-results/
-
2 Replies
-
Het zijn zeker goede resultaten. De brutowinstmarge is flink hoger, maar de operationele kosten waren ook hoger, omdat men natuurlijk het verkoopteams moet uitbreiden. Minder cash verbranding en er staat nog $48 miljoen cash op de bank.
-
Yup. Verlammende angst, kwellende onzekerheid en kwakkelend beursklimaat zorgen er ondertussen voor dat de koers (erg) laag blijft. We breiden onze positie ondertussen rustig verder uit. Blik op de LT toekomst …
-
Log in to reply.